跳至主要内容
临床试验/NCT00723216
NCT00723216已完成3 期

Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.

Sanofi1 个研究点 分布在 1 个国家目标入组 151 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Sanofi
入组人数
151
试验地点
1
主要终点
Venous thromboembolism incidence

研究概览

简要总结

The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery. The secondary objective is evaluate the incidence of adverse events of enoxaparin in these patients.

研究设计

研究类型
Interventional
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Malignant tumor patients undergoing laparotomy for which surgery is expected to take 45 minutes or more.

排除标准

  • surgery under laparoscope and other endoscopic operations
  • clinical signs of deep vein thrombosis
  • use of non-steroidal anti-inflammatory drugs from surgery completion until initial administration
  • severe hepatic disease or renal disease
  • women of childbearing potential, pregnant or lactating.

研究组 & 干预措施

1

Active Comparator

Enoxaparin

干预措施: enoxaparin (Drug)

2

Other

Intermittent Pneumatic Compression (IPC)

干预措施: Physical prophylaxis (Other)

结局指标

主要结局

Venous thromboembolism incidence

时间窗: 28 days

次要结局

  • Incidence of deep vein thrombosis, pulmonary thromboembolism, and venous thromboembolism incidence except patients with thrombus only in muscle veins, and incidence of proximal vein thrombosis(28 days)

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验